Literature DB >> 12627480

Epidemiology of Varicella-Zoster Virus in England and Wales.

M Brisson1, W J Edmunds.   

Abstract

Many countries are studying currently the possibility of mass vaccination against varicella. The objective of this study was to provide a complete picture of the pre-vaccine epidemiology of the Varicella-Zoster Virus in England and Wales to aid in the design of immunisation programs. Population-based data including general practitioner sentinel surveillance, hospitalisation data, and death certificates from England and Wales were analysed. The average incidence rates for varicella and zoster between 1991 and 2000 were 1,291 and 373 per 100,000 years, respectively. Overall hospitalisation rates were equal for varicella and zoster (4.5 vs. 4.4 hospitalisation per 100,000 population) with 5 and 8%, respectively, having underlying immunosuppressive conditions. The age-specific proportion of cases hospitalised and length of stay were similar between the two diseases. However, the overall burden of disease is considerably higher for zoster. The number of inpatient days and case-fatality due to zoster are roughly 4 to 6 times greater than for varicella (11 vs. 3 days and 25 vs. 4 deaths per 100,000 case). These results provide base-line estimates should mass varicella vaccination be introduced in England and Wales. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12627480     DOI: 10.1002/jmv.10313

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  46 in total

1.  Varicella vaccination in England and Wales: cost-utility analysis.

Authors:  M Brisson; W J Edmunds
Journal:  Arch Dis Child       Date:  2003-10       Impact factor: 3.791

2.  Secular trends in the epidemiology of shingles in Alberta.

Authors:  M L Russell; D P Schopflocher; L Svenson; S N Virani
Journal:  Epidemiol Infect       Date:  2007-02-12       Impact factor: 2.451

3.  Estimating the number needed to vaccinate to prevent herpes zoster-related disease, health care resource use and mortality.

Authors:  Marc Brisson
Journal:  Can J Public Health       Date:  2008 Sep-Oct

4.  Comparing shingles incidence and complication rates from medical record review and administrative database estimates: how close are they?

Authors:  Barbara P Yawn; Peter Wollan; Jennifer St Sauver
Journal:  Am J Epidemiol       Date:  2011-09-13       Impact factor: 4.897

5.  Severe complications of chickenpox in hospitalised children in the UK and Ireland.

Authors:  J C Cameron; G Allan; F Johnston; A Finn; P T Heath; R Booy
Journal:  Arch Dis Child       Date:  2007-11-08       Impact factor: 3.791

6.  Compliance with herpes zoster vaccination in young and adult individuals in two regions of Italy.

Authors:  Antonino Parlato; Vincenzo Romano Spica; Massimo Ciccozzi; Francesca Farchi; Francesca Gallè; Valeria Di Onofrio; Elisabetta Franco; Giorgio Liguori
Journal:  BMC Public Health       Date:  2010-06-12       Impact factor: 3.295

7.  Impact of herpes zoster and post-herpetic neuralgia on patients' quality of life: a patient-reported outcomes survey.

Authors:  Thomas Weinke; Alexander Edte; Sonja Schmitt; Kati Lukas
Journal:  Z Gesundh Wiss       Date:  2010-03-21

8.  Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study.

Authors:  Leonardo Emberti Gialloreti; Monica Merito; Patrizio Pezzotti; Luigi Naldi; Antonio Gatti; Maud Beillat; Laurence Serradell; Rafaelle di Marzo; Antonio Volpi
Journal:  BMC Infect Dis       Date:  2010-08-03       Impact factor: 3.090

9.  Burden of herpes zoster requiring hospitalization in Spain during a seven-year period (1998-2004).

Authors:  Angel Gil; Ruth Gil; Alejendro Alvaro; María San Martín; Antonio González
Journal:  BMC Infect Dis       Date:  2009-05-07       Impact factor: 3.090

Review 10.  Postherpetic neuralgia in the elderly.

Authors:  R W Johnson; J McElhaney
Journal:  Int J Clin Pract       Date:  2009-09       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.